Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

CP, Cannon; DK, McGuire; R, Pratley; S, Dagogo-Jack; J, Mancuso; S, Huyck; B, Charbonnel; WJ, Shih; S, Gallo; U, Masiukiewicz; G, Golm; F, Cosentino; B, Lauring; SG, Terra

doi:10.1016/j.ahj.2018.08.016

Public

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

Shared by NobleBlocks on Sep 5, 2018 • 12:00 AM UTC

Authors:

Cannon CP

McGuire DK

Pratley R

Abstract

<h4>Background</h4>Ertugliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), approved in the United States and European Union to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). The VERTIS cardiovascular (CV) outcomes trial (NCT01986881) has a primary objectiv...

Discussions